Prognostic Impact of lncRNA MCM3AP-AS1 Expression in Malignant Solid Tumors: A Systematic Review and Meta-analysis

Abstract Objectives: MCM3AP-AS1 is a newly discovered long non-coding RNA that functions as a biomarker in many different cancer types. However, the pooled role of lncRNA MCM3AP-AS1 in the prognosis of human cancers remains unclear. We performed a systematic review and meta-analysis to explore its potential prognosis for malignant tumors. Materials and methods: A literature survey was conducted by searching in the PubMed, Embase, Web of Science, China National Knowledge Infrastructure and Wanfang databases for studies published as of September 1, 2021. The pooled hazard ratio (HR) and 95% confidence interval (95% CI) were calculated to evaluate the relationship between MCM3AP-AS1 expression and overall survival (OS). The endpoints also included various clinical parameters. Results: A total of 14 studies containing 921 cancer patients were finally included into this meta-analysis. The results comprehensively showed that increased MCM3AP-AS1 expression was significantly correlated with poor overall survival (HR = 1.83, 95% CI: 1.56-2.14, P<0.00001). A subgroup meta-analysis for overall survival was conducted. Additionally, high level of lncRNA MCM3AP-AS1 was significantly associated with worse differentiation (OR = 1.76, 95 % CI: 1.12–2.75, P = 0.01), larger tumor size (OR = 2.70, 95 % CI: 1.13–6.46, P = 0.03), advanced clinical stage (OR = 2.52, 95 % CI: 1.32–4.81, P = 0.005) and lymph node metastasis (OR = 2.85, 95 % CI: 1.16–7.00, P = 0.02), respectively. Conclusions: LncRNA MCM3AP-AS1 might be a potential and unfavorable prognostic biomarker of cancer.

Download Full-text

Prognostic Role of Tissue and Circulating MicroRNA-200c in Malignant Tumors: a Systematic Review and Meta-Analysis

Cellular Physiology and Biochemistry ◽

10.1159/000373943 ◽

2015 ◽

Vol 35 (3) ◽

pp. 1188-1200 ◽

Cited By ~ 14

Author(s):

Yingjie Shao ◽

Yiting Geng ◽

Wendong Gu ◽

Jin Huang ◽

Honglei Pei ◽

...

Keyword(s):

Systematic Review ◽

Malignant Tumors ◽

Early Stage ◽

Meta Analysis ◽

Cochrane Library ◽

Circulating Microrna ◽

Prognostic Role ◽

Altered Expression ◽

High Level

Background: Recently, many studies have shown that microRNAs (miRNA) exhibit altered expression in various cancers and may serve as prognostic biomarkers. We performed a systematic review and meta-analysis to evaluate the prognostic role of miR-200c expression in different cancers. Methods: Studies were recruited by searching PubMed, Embase and the Cochrane Library (last search update was May 2014) and assessed by further quality evaluation. Results: A total of 25 studies dealing with various carcinomas were identified for systematic review. Among them, 18 studies were ultimately included in the meta-analysis. Our results indicated that the expression of tissue miR-200c was not associated with OS and PFS in various carcinomas; however, downregulation of tissue miR-200c did predict poor OS of patients with stage I disease (HR=0.41, 95% CI 0.25-0.68, P=0.001). Furthermore, overexpression of blood miR-200c was significantly related to poor OS and PFS (HR=3.07 95% CI 1.58-5.96 P=0.001, HR=2.26 95% CI 1.66-3.08 P<0.001, respectively), especially in patients with advanced disease. Conclusion: This systematic review and meta-analysis clarified that low expression of miR-200c in primary tissue was significantly associated with poor survival in cancer patients at early stage, whereas a high level of blood miR-200c predicted poor prognosis in patients with advanced tumors.

Download Full-text

Clinical and Prognostic Implications of P21 (WAF1/CIP1) Expression in Patients with Esophageal Cancer: A Systematic Review and Meta-Analysis

Disease Markers ◽

10.1155/2020/6520259 ◽

2020 ◽

Vol 2020 ◽

pp. 1-12 ◽

Cited By ~ 1

Author(s):

Junbo Wu ◽

Liang Liu ◽

Feng Wu ◽

Li Qiu ◽

Ming Luo ◽

...

Keyword(s):

Systematic Review ◽

Esophageal Cancer ◽

Prognostic Factor ◽

Clinical Outcomes ◽

Publication Bias ◽

Malignant Tumors ◽

Meta Analysis ◽

Clinical Stage ◽

Clinicopathological Characteristics ◽

Response To Chemotherapy

Background. Previous studies have demonstrated that P21 (WAF1/CIP1) is a valuable prognostic factor in several malignant tumors. However, it is not known whether P21 can predict the prognosis in patients with esophageal cancer (EC). The aim of this research was to investigate the contribution of P21 expression to the clinicopathological characteristics and of EC. Methods. A systematic review and meta-analysis of study focusing on P21 expression, clinicopathological characteristics, and clinical outcomes in patients with EC was performed using seven databases (PubMed, Embase, Web of Science, and four Chinese databases). Pooled hazard ratios and odds ratios were used to explore the association between P21 expression, clinicopathological characteristics, and outcomes in patients with EC. The heterogeneity of the studies was classified by the I2 statistic. The sensitivity analysis was then utilized to assess the robustness of the results. Finally, the funnel plot and Begg’s test were used to evaluate the publication bias. Results. Forty-five studies with 3098 patients were eligible for inclusion in the meta-analysis. Thirty of these studies reported on clinicopathological characteristics and 15 on clinical outcomes. The pooled hazard ratio of 1.456 (95% confidence intervals 1.033–2.053, P=0.032) for overall survival indicated that a low P21 expression level was an unfavorable prognostic factor for a clinical outcome in patients with EC. Furthermore, the pooled odds ratio confirmed an association between decreased P21 expression and poor clinicopathological characteristics, including differentiation, lymph node metastasis, invasion, and higher grade and clinical stage. Notably, high P21 expression was a significant predictor of a favorable response to chemotherapy. There was no evidence of publication bias. Conclusion. Reduced P21 expression is associated with a poor outcome in patients with EC.

Download Full-text

Prognostic Role of MicroRNA-126 for Survival in Malignant Tumors: A Systematic Review and Meta-Analysis

Disease Markers ◽

10.1155/2015/739469 ◽

2015 ◽

Vol 2015 ◽

pp. 1-11 ◽

Cited By ~ 6

Author(s):

Jie Bu ◽

Hui Li ◽

Xiao-yang Li ◽

Li-hong Liu ◽

Wei Sun ◽

...

Keyword(s):

Systematic Review ◽

Malignant Tumors ◽

Meta Analysis ◽

Cochrane Library ◽

Prognostic Role ◽

Patients With Cancer ◽

Hazard Ratios ◽

High Level ◽

The Cochrane Library

Background.Increasing studies found that miR-126 expression may be associated with the prognosis of cancers. Here, we performed a meta-analysis to assess the prognostic role of miR-126 in different cancers.Methods.Eligible studies were identified by searching in PubMed, Embase, the Cochrane Library, CNKI, and Wan Fang databases up to March 2015. Pooled hazard ratios (HRs) and their corresponding 95% confidence intervals (CIs) were calculated to investigate the correlation between miR-126 and survival of cancers.Results.Thirty studies including a total of 4497 participants were enrolled in this meta-analysis. The pooled results showed that high level of miR-126 was a predictor for favorable survival of carcinomas, with pooled HR of 0.77 (95% CI 0.64–0.93) for OS, 0.64 (95%CI 0.48–0.85) for DFS, and 0.70 (95% CI 0.50–0.98) for PFS/RFS/DSS. However, high level of circulating miR-126 predicted a significantly worse OS in patients with cancer (HR = 1.65, 95% CI 1.09–2.51).Conclusions.Our results indicated that miR-126 could act as a significant biomarker in the prognosis of various cancers.

Download Full-text

Prognostic and clinical significance of long non-coding RNA SNHG12 expression in various cancers

10.21203/rs.3.rs-18849/v1 ◽

2020 ◽

Author(s):

Chenghao Zhang ◽

Chao Tu ◽

Xiaolei Ren ◽

Wenchao Zhang ◽

Lile He ◽

...

Keyword(s):

Overall Survival ◽

Meta Analysis ◽

Clinical Stage ◽

The Cancer Genome Atlas ◽

Clinicopathological Parameters ◽

Tumor Type ◽

Advanced Clinical Stage ◽

Non Coding Rna ◽

Tcga Dataset ◽

Stratified Analysis

Abstract Background: Recently, dysregulation of lncRNA SNHG12 has been determined in kinds of cancers. However, definite prognostic value of SNHG12 remains unclear. We conducted this meta-analysis to evaluate the association between SNHG12 expression levels and caner prognosis.Methods: A literature retrieval was conducted by searching kinds of databases. The meta-analysis of prognostic and clinicopathological parameters was performed by using Revman 5.2 and Stata 12.0 software. Besides, The Cancer Genome Atlas dataset was analyzed to validate the results in our meta-analysis via using Gene Expression Profiling Interactive Analysis.Results: High SNHG12 expression significantly predicted worse overall survival (HR=1.97, 95%CI 1.56-2.48, P<0.01) and recurrence-free survival (HR=1.71, 95%CI 1.05-2.78, P<0.01). Tumor type, sample size, survival analysis method, and cut-off value did not alter SNHG12 prognosis value according to stratified analysis results. Additionally, patients with elevated SNHG12 expression were more prone to unfavorable clinicopathological outcomes, including larger tumor size, lymph node metastasis, distant metastasis, advanced clinical stage. Online cross-validation in TCGA dataset further proved that cancer patients with upregulated SNHG12 expression had worse overall survival and disease-free survival.Conclusion: Elevated SNHG12 expression was associated with poor survival and unfavorable clinicopathological features in various cancers, and therefore might be a potential prognostic biomarker in human cancers.

Download Full-text

Expression of tripartite motif‑containing 44 and its prognostic and clinicopathological value in human malignancies：a meta-analysis

10.21203/rs.3.rs-15897/v3 ◽

2020 ◽

Author(s):

Guoliang Xiao ◽

Qiuxi Yang ◽

Ziwei Bao ◽

Haixia Mao ◽

Yi Zhang ◽

...

Keyword(s):

Malignant Tumors ◽

Meta Analysis ◽

Clinical Stage ◽

Mrna Level ◽

Disease Free Survival ◽

Expression Level ◽

Advanced Clinical Stage ◽

Normal Tissues ◽

Tripartite Motif ◽

Elevated Expression

Abstract Background: Previous researches have reported that tripartite motif-containing 44 (TRIM44) is related to the prognosis of multiple human tumors. This study was designed to systematically assess the prognostic value of TRIM44 in human malignancies and summarize its possible tumor-related mechanisms.Methods: The available databases were searched for eligible studies that evaluated the clinicopathological and prognostic roles of TRIM44 in patients with malignancies. The hazard ratios (HR) and odds ratios (OR) were combined to assess the predictive role of TRIM44 using Stata/SE 14.1 software.Results: A total of 1,740 patients from thirteen original studies were finally included in this study. The results of the combined analysis showed that over-expression of TRIM44 protein was significantly correlated with shorter overall survival (OS) (HR = 1.94, 95% CI: 1.60-2.35) and worse disease-free survival (DFS) (HR= 2.13, 95% CI: 1.24-3.65) in cancer patients. Additionally, the combined ORs indicated that elevated expression level of TRIM44 protein was significantly associated with lymph node metastasis (OR=2.69, 95% CI: 1.71-4.24), distant metastasis (OR=10.35, 95% CI: 1.01-106.24), poor tumor differentiation (OR=1.78, 95% CI: 1.03-3.09), increased depth of tumor invasion (OR=2.72, 95% CI: 1.73-4.30), advanced clinical stage (OR=2.75, 95% CI: 2.04-3.71), and recurrence (OR=2.30, 95% CI: 1.34-3.95). Furthermore, analysis results using Gene Expression Profiling Interactive Analysis (GEPIA) showed that the expression level of TRIM44 mRNA was higher in most tumor tissues than in the corresponding normal tissues, and the relationship between TRIM44 mRNA level and prognosis in various malignant tumors also explored in GEPIA and OS analysis webservers.Conclusions: TRIM44 may serve as a valuable prognostic biomarker and a potential therapeutic target for patients with malignancies.

Download Full-text

Systematic review and meta-analysis of prognostic microRNA biomarkers for survival outcome in laryngeal squamous cell cancer

Cancer Cell International ◽

10.1186/s12935-021-02021-8 ◽

2021 ◽

Vol 21 (1) ◽

Author(s):

Yan Huang ◽

Min Gu ◽

Yiting Tang ◽

Zhiqiang Sun ◽

Judong Luo ◽

...

Keyword(s):

Systematic Review ◽

Overall Survival ◽

Laryngeal Cancer ◽

Meta Analysis ◽

Clinical Stage ◽

Cell Cancer ◽

Disease Free Survival ◽

Cochrane Library ◽

Rare Type ◽

Laryngeal Mucosa

Abstract Background Laryngeal carcinoma is a primary malignant tumor originating from the laryngeal mucosa, and its pathogenesis is not fully understood. It is a rare type of cancer that shows a downward trend in the 5-year survival rate. In clinical practice, dysregulated microRNAs are often observed in patients with laryngeal cancer. In recent years, an increasing number of studies have confirmed that the strong biomarker potential of microRNAs. We conducted a systematic review and meta-analysis to identify and highlight multiple microRNAs as biomarkers for disease prognosis in patients with laryngeal cancer. Methods We actively searched the systematic reviews in PubMed, Embase, Web of Science and The Cochrane Library to select the studies that met the proposed guidelines. A total of 5307 patients with laryngeal cancer were included in this study to evaluate the association between microRNAs expression levels and patient outcomes. For overall survival in the clinical stage, a hazard ratio (HR) and corresponding 95% confidence interval (CI) are calculated to assess the effect of survival. Results A total of 36 studies on microRNAs and laryngeal cancer recovery were included in this meta-analysis. The selected endpoints for these studies included overall survival (OS) and disease-free survival (DFS).The comorbidities of overexpression and underexpression of microRNAs were 1.13 (95% CI 1.06–1.20, P < 0.05) and 1.10 (95% CI 1.00–1.20, P < 0.05), respectively. Conclusion MiRNA-100, miRNA-155, miRNA-21, miRNA-34a, miRNA-195 and miR-let-7 are expected to be potential noninvasive and simple markers for laryngeal cancer.

Download Full-text

Prognostic value of cripto-1 expression in non-small-cell lung cancer patients: a systematic review and meta-analysis

Biomarkers in Medicine ◽

10.2217/bmm-2019-0159 ◽

2020 ◽

Vol 14 (4) ◽

pp. 317-329

Author(s):

Yuanfeng Wei ◽

Jinfang Jiang ◽

Chengyan Wang ◽

Hong Zou ◽

Xihua Shen ◽

...

Keyword(s):

Lung Cancer ◽

Systematic Review ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Meta Analysis ◽

Clinical Stage ◽

Small Cell ◽

Small Cell Lung ◽

Poor Overall Survival ◽

Nsclc Patients

Aim: This systematic review and meta-analysis aimed to analyze the association between cripto-1 expression and prognosis as well as clinicopathological features of non-small-cell lung cancer (NSCLC) patients. Methods: The electronic databases for all articles about NSCLC and cripto-1 expression were searched. Results: Twelve articles were enrolled in this meta-analysis (3130 samples). In NSCLC patients, cripto-1 was expressed higher than in normal tissues. Cripto-1 expression was closely correlated with lymph node metastasis, histological differentiation and advanced clinical stage of NSCLC patients, but not related to smoking, age and gender. Pooled hazard ratios found that high cripto-1 expression had poor overall survival and progression-free survival. Conclusion: Cripto-1 could serve as a novel biomarker for predicting poor prognosis in NSCLC patients.

Download Full-text

PTH-289 The poor overall survival of right-sided colon cancer compared with left-sided colon cancers: a systematic review and meta-analysis

Gut ◽

10.1136/gutjnl-2015-309861.1177 ◽

2015 ◽

Vol 64 (Suppl 1) ◽

pp. A538.1-A538

Author(s):

M Yahagi ◽

K Okabayashi ◽

H Hasegawa ◽

M Tsuruta ◽

T Kondo ◽

...

Keyword(s):

Systematic Review ◽

Colon Cancer ◽

Overall Survival ◽

Meta Analysis ◽

Poor Overall Survival ◽

Colon Cancers ◽

The Poor

Download Full-text

The Prognostic value of the Fibrinogen to pre-albumin ratio in malignant tumors of the digestive system: a systematic review and meta-analysis

Cancer Cell International ◽

10.1186/s12935-022-02445-w ◽

2022 ◽

Vol 22 (1) ◽

Author(s):

Baibei Li ◽

Huachu Deng ◽

Ziyan Zhou ◽

Bo Tang

Keyword(s):

Systematic Review ◽

Prognostic Value ◽

Digestive System ◽

Malignant Tumors ◽

Meta Analysis ◽

Disease Free Survival ◽

Poor Overall Survival ◽

Cancer Specific Survival ◽

Free Survival ◽

Albumin Ratio

Abstract Background In recent years, the Fibrinogen to pre-albumin ratio (FPR) has been reported in many studies to be significantly associated with the prognosis of various cancers. This systematic review and meta-analysis aimed to investigate the prognostic value of FPR in malignant tumors of the digestive system based on available evidence. Methods The relevant articles published before July 1, 2021, were systematically retrieved from electronic databases to evaluate the effect of Fibrinogen to pre-albumin ratio (FPR) on the prognosis of patients with malignant digestive system tumors and calculate the hazard ratio (HR) and the corresponding 95% confidence interval (CI). Result Thirteen articles, all from China, including 15 cohort studies and a total of 5116 cases, were included in this study. A high FPR was associated with poor overall survival (HR = 1.88, 95%CI 1.53–2.32, P < 0.001), recurrence-free survival (HR = 2.29, 95%CI 1.91–2.76, P < 0.001), progression-free survival (HR = 1.96, 95%CI: 1.33–2.90, P = 0.001), complications (HR = 1.78, 95%CI: 1.06–3.00, P = 0.029), disease-free survival (HR = 1.46, 95%CI: 1.08–1.97, P = 0.013) was significantly associated with cancer-specific survival (HR = 1.44, 95%CI: 1.15–1.79, P = 0.001). Even though intergroup differences were present, FPR was strongly associated with overall and relapse-free survival, and sensitivity analysis suggested that our results were stable. Conclusion FPR can be used as a valuable indicator to predict the prognosis of patients with malignant digestive system tumors.

Download Full-text